Thermo Fisher Scientific Inc. (NYSE:TMO) completed the previously announced sale of its Anatomical Pathology business to PHC Holdings Corporation, a leading global healthcare company providing innovative solutions, for approximately $1.14 billion in cash. The Anatomical Pathology business, with approximately 1200 employees in the U.S., Europe and Asia, generated approximately $350 million in annual revenue and was part of Thermo Fisher’s Specialty Diagnostics Segment.
The stock Earnings per share (EPS) and the diluted EPS are the profitability measures used in the fundamental analysis of companies. The figure of EPS only takes into account a Thermo Fisher Scientific Inc. (NYSE:TMO) common shares, whereas the very important diluted EPS take into account all the convertible securities such as convertible bonds/convertible preferred stock, which are changed into equity or common stock. Dilutive effects occur when the number of shares increases, for example, through a new issue. If a company issues more shares to shareholders and other investors, this increases the number of shares outstanding and decreases the company’s earnings per share. Ultimately, this can decrease the stock price.Thermo Fisher Scientific Inc. (NYSE:TMO) Diluted EPS is 7.90, whereas the EPS Estimate for next year is 13.55. The Annual EPS Growth of past 5 years is 16.60% and Thermo Fisher Scientific Inc. (NYSE:TMO) yearly performance is 44.40% and net profit margin is 12.90%.
Key Performance indicators for Thermo Fisher Scientific Inc. (NYSE:TMO), in last 4 months the performance of TMO was 7.29% while its price to sale ratio is 4.77 and price to book ratio is 4.24. Company gross margin stands at 44.60% whereas its return on investment (ROI) is 7.70%.
On 28 June 2019, Thermo Fisher Scientific Inc. (NYSE:TMO), a Healthcare sector firm, traded 5.25 Million shares in last trading session and stock moved down -0.03% with closing price of $293.68 per share. with Thermo Fisher Scientific Inc. (NYSE:TMO) traded 5.25 Million shares. The TMO distance from 20 day simple moving average is 3.24% and distance from 50-Day simple moving average is 6.88%.The relative strength index for stock is 66.76 and Average true range of TMO is 4.80.
Analyst’s mean target price for TMO is $296.63 while analysts mean recommendation is 1.70. The Stock value has moved between $202.54 – 299.67 in last one year. TMO market capitalization is 117501.37 with beta of 1.11. Company has 0.20% insider ownership.
Thermo Fisher Scientific Inc. (NYSE:TMO) is under coverage by number of analysts. Stock has got OUTPERFORM rating from 5 of Thomson Reuters analysts, 3 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Buy rating has been given by 10 analysts to the company stock.